MODERN APPROACHES TO THE TREATMENT OF ISCHEMIC HEART DISEASE

JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 01, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL Associate Professor of the Department of Internal Diseases, Andijan State Medical Institute, Yuldasheva Gulnora Bakhtiyarovna Доцент кафедры внутренних болезней Андижанского государственного медицинского института Юлдашева Гульнора Бахтияровна Andijon davlat tibbiyot instituti ichki kasalliklar kafedrasi dotsenti Yuldasheva Gulnora Baxtiyarovna MODERN APPROACHES TO THE TREATMENT OF ISCHEMIC HEART DISEASE Abstract: Ischemic heart disease (IHD) remains one of the most pressing global health challenges, ranking among the leading causes of mortality and disability worldwide. The pathogenesis of the disease is primarily associated with atherosclerosis, coronary artery spasm, and thrombosis. This article highlights current strategies for the management of IHD. In pharmacotherapy, the efficacy of antiplatelet agents (aspirin, clopidogrel), statins, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin II receptor blockers is reviewed. In interventional cardiology, coronary angioplasty and stenting are widely applied, often in combination with non-invasive diagnostic techniques. In complex cases, coronary artery bypass grafting remains an effective surgical option. Recent years have seen increasing attention to minimally invasive technologies, novel antithrombotic drugs, and advances in regenerative medicine, including stem cell and gene therapies. Preventive measures, risk factor modification, and the promotion of a healthy lifestyle play a crucial role in improving treatment outcomes and reducing the risk of IHD recurrence. Keywords: ischemic heart disease, modern treatment, pharmacotherapy, angioplasty, stenting, coronary artery bypass grafting, prevention. YURAK ISHEMIK KASALLIGINI DAVOLASHNING ZAMONAVIY USULLARI Anotatsiya: Yurak ishemik kasalligi (YIK) global sog‘liqni saqlash tizimi oldida eng dolzarb muammolardan biri bo‘lib, o‘lim va nogironlikning yetakchi sabablaridan hisoblanadi. Kasallikning patogenezida ateroskleroz, koronar tomirlar spazmi va tromboz asosiy o‘rin tutadi. Maqolada YIKni davolashda qo‘llanilayotgan zamonaviy yondashuvlar batafsil yoritilgan. Farmakoterapiya yo‘nalishida antiplatelet preparatlar (aspirin, klopidogrel), statinlar, betablokatorlar, AKF ingibitorlari hamda angiotenzin II retseptor blokatorlarining klinik samaradorligi ko‘rib chiqiladi. Intervensiya kardiologiyasida koronar angioplastika va stentlash keng qo‘llanilib, ular invaziv bo‘lmagan diagnostika usullari bilan uyg‘unlashtirilmoqda. Shuningdek, murakkab holatlarda koronar shuntlash operatsiyasi samarali usul sifatida tavsiya etiladi. So‘nggi yillarda minimal invaziv texnologiyalar, yangi avlod antitrombotsitar dorilar hamda regenerativ tibbiyot imkoniyatlari (ildiz hujayra terapiyasi, gen terapiyasi) yuzasidan tadqiqotlar olib borilmoqda. Profilaktik choralar, xavf omillarini nazorat qilish va sog‘lom turmush tarzini shakllantirish YIK davolash samaradorligini oshirish va qaytalanishini kamaytirishda muhim ahamiyat kasb etadi. JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 01, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL Kalit so‘zlar: yurak ishemik kasalligi, zamonaviy davolash, farmakoterapiya, angioplastika, stentlash, shuntlash, profilaktika. СОВРЕМЕННЫЕ МЕТОДЫ ЛЕЧЕНИЯ ИШЕМИЧЕСКОЙ БОЛЕЗНИ СЕРДЦА Аннотация: Ишемическая болезнь сердца (ИБС) является одной из наиболее актуальных проблем современного здравоохранения, занимая ведущие позиции среди причин смертности и инвалидизации населения. В патогенезе заболевания основную роль играют атеросклероз, спазм и тромбоз коронарных артерий. В статье подробно освещены современные подходы к лечению ИБС. В фармакотерапии рассматривается эффективность антиагрегантов (аспирин, клопидогрел), статинов, бета-адреноблокаторов, ингибиторов ангиотензинпревращающего фермента (иАПФ) и блокаторов рецепторов ангиотензина II. В интервенционной кардиологии широкое применение находят коронарная ангиопластика и стентирование, которые нередко сочетаются с неинвазивными методами диагностики. В сложных случаях коронарное шунтирование остается эффективным хирургическим методом. В последние годы активно исследуются минимально инвазивные технологии, препараты нового поколения, а также возможности регенеративной медицины (стволовые клетки, генная терапия). Отмечается важность профилактических мероприятий, контроля факторов риска и формирования здорового образа жизни для повышения эффективности лечения и снижения риска рецидива ИБС. Ключевые слова: ишемическая болезнь сердца, современные методы лечения, фармакотерапия, ангиопластика, стентирование, коронарное шунтирование, профилактика. Introduction Ischemic heart disease (IHD) is one of the most prevalent cardiovascular disorders and remains a major global health challenge. According to the World Health Organization, cardiovascular diseases account for nearly half of all deaths worldwide, with IHD representing a significant proportion. The pathogenesis of IHD is primarily linked to atherosclerosis, coronary artery spasm, and thrombosis. Clinically, it manifests as angina pectoris, cardiac arrhythmias, heart failure, and acute myocardial infarction. In recent decades, treatment strategies for IHD have advanced considerably. Pharmacological therapy has expanded with the use of novel antiplatelet agents, lipid-lowering drugs, betablockers, and renin-angiotensin system inhibitors. The rapid development of interventional cardiology has made coronary angioplasty and stenting widely available, while coronary artery bypass grafting remains an effective surgical option in severe cases. Moreover, regenerative medicine, gene therapy, and minimally invasive techniques are emerging as promising therapeutic approaches. Therefore, the investigation of modern treatment methods for ischemic heart disease and the evaluation of their clinical effectiveness remain highly relevant both scientifically and practically. Literature Review Over the past decades, numerous studies have been conducted on the treatment of ischemic heart disease (IHD). According to the World Health Organization (WHO, 2023), IHD remains one of the leading causes of mortality worldwide, highlighting the importance of comprehensive management and prevention strategies. JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 01, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL Pharmacotherapy. The efficacy of antiplatelet agents such as aspirin and clopidogrel has been confirmed in large-scale clinical trials (Antithrombotic Trialists’ Collaboration, 2019). Statins have been shown to lower cholesterol levels, slow the progression of atherosclerosis, and reduce cardiovascular events (Stone et al., 2020). Beta-blockers and ACE inhibitors remain essential in preventing recurrent myocardial infarction and managing heart failure. Interventional cardiology. Coronary angioplasty and stenting have become widely used treatment modalities. The introduction of drug-eluting stents has significantly reduced restenosis rates (Windecker et al., 2022). Coronary artery bypass grafting continues to be the most effective option for patients with multivessel or complex coronary lesions. Emerging therapeutic directions. Regenerative medicine has gained increasing attention. Early clinical trials involving stem cell transplantation and gene therapy have demonstrated potential improvements in myocardial perfusion (Menasché, 2018). Additionally, minimally invasive procedures, robotic-assisted surgeries, and next-generation antithrombotic agents are showing promising clinical outcomes. Overall, the literature indicates that an integrated approach combining pharmacotherapy, interventional techniques, and surgical options provides the most effective management of IHD. Preventive strategies and lifestyle modification remain fundamental in reducing disease incidence and recurrence. Results The analysis of contemporary literature and clinical studies demonstrates that the most effective management of ischemic heart disease (IHD) is achieved through a comprehensive approach combining pharmacological, interventional, surgical, and preventive strategies. 1. Pharmacotherapy. Antiplatelet therapy (aspirin, clopidogrel) has been shown to reduce cardiovascular events by 20–25%. Statins slow the progression of atherosclerosis and lower the risk of myocardial infarction by up to 30%. Beta-blockers and ACE inhibitors reduce the incidence of heart failure and improve overall survival. 2. Interventional cardiology. Drug-eluting stents have decreased restenosis rates by more than 50% compared with bare-metal stents. Coronary angioplasty provides rapid symptomatic relief, while coronary artery bypass grafting (CABG) offers superior long-term outcomes in patients with complex lesions. 3. Innovative approaches. Clinical trials indicate that stem cell therapy can enhance myocardial perfusion and improve ejection fraction. Early studies in gene therapy have also yielded promising results, although further investigation is necessary before widespread clinical adoption. 4. Prevention. Lifestyle modifications such as smoking cessation, increased physical activity, and balanced nutrition significantly reduce recurrence rates and improve long-term prognosis. Overall, the results suggest that an integrated approach—combining pharmacotherapy, interventional techniques, surgical options, and preventive strategies—is the most effective way to improve clinical outcomes and enhance the quality of life for patients with IHD. Discussion The analysis indicates that ischemic heart disease (IHD) remains a major public health challenge due to its high prevalence, disability burden, and mortality rate. While modern treatment methods JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 01, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL provide significant benefits, each has limitations, highlighting the need for a comprehensive therapeutic approach. Pharmacotherapy has proven effective in reducing cardiovascular complications, particularly through the use of antiplatelet agents and statins. However, adverse drug reactions and insufficient response in some patients limit its role as a stand-alone treatment. Interventional cardiology (angioplasty and stenting) offers rapid symptomatic relief, yet restenosis remains a concern despite advances in drug-eluting stents. Coronary artery bypass grafting (CABG) provides superior long-term outcomes in patients with multivessel disease, but surgical risks and prolonged recovery represent important limitations. Innovative approaches such as regenerative medicine, stem cell transplantation, and gene therapy have shown promising preliminary results. Nevertheless, further large-scale clinical trials are required before these methods can be widely adopted in practice. In conclusion, an integrated strategy that combines pharmacotherapy, interventional techniques, surgical treatment, and preventive measures — including lifestyle modification — represents the most effective way to improve prognosis and reduce recurrence of IHD. Conclusion and Recommendations Ischemic heart disease (IHD) remains one of the leading causes of death and disability worldwide. Modern treatment strategies — including pharmacotherapy, interventional and surgical procedures, as well as innovative biotechnological approaches — have significantly improved patient outcomes. Nevertheless, each method has its own limitations, making an integrated approach the most effective strategy. Combining drug therapy with interventional or surgical techniques, along with lifestyle modification, ensures the best results in reducing complications and preventing recurrence. Recommendations: 1. Strengthen early detection and preventive strategies for IHD risk factors. 2. Apply pharmacotherapy based on personalized treatment approaches. 3. Expand the use of advanced interventional and surgical technologies. 4. Continue research in regenerative medicine and gene therapy. 5. Promote healthy lifestyle programs as a cornerstone of prevention. References 1. World Health Organization (WHO). Cardiovascular diseases (CVDs): Key facts. Geneva: WHO; 2023. 2. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal. 2018;39(2):119–177. 3. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. European Heart Journal. 2020;41(3):407–477. 4. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the management of ST-elevation myocardial infarction. Journal of the American College of Cardiology. 2013;61(4):e78–e140. JOURNAL OF IQRO – ЖУРНАЛ ИҚРО – IQRO JURNALI – volume 18, issue 01, 2025 ISSN: 2181-4341, IMPACT FACTOR ( RESEARCH BIB ) – 7,245, SJIF – 5,431 www.wordlyknowledge.uz ILMIY METODIK JURNAL 5. Yusuf S, Hawken S, Ôunpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet. 2004;364(9438):937–952. 6. Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. New England Journal of Medicine. 2007;356(15):1503–1516. 7. Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused Update for the diagnosis and management of patients with stable ischemic heart disease. Journal of the American College of Cardiology. 2014;64(18):1929–1949. 8. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. New England Journal of Medicine. 2010;362(18):1663–1674. 9. Madonna R, Van Laake LW, Davidson SM, et al. Position paper of the ESC Working Group on Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration. European Heart Journal. 2016;37(23):1789–1798. 10. Virani SS, Alonso A, Aparicio HJ, et al. Heart disease and stroke statistics — 2021 update: A report from the American Heart Association. Circulation. 2021;143(8):e254–e743.